CRISPR Therapeutics (CRSP) Earnings Date, Estimates & Call Transcripts $41.09 +0.15 (+0.37%) (As of 02:23 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CRISPR Therapeutics Latest Earnings SummaryActual EPS (Nov. 5) -$1.01 Beat By $0.41 Consensus EPS (Nov. 5) -$1.42 CRISPR Therapeutics released Q3 2024 earnings on November 5, 2024, reporting an EPS of -$1.01, which beat the consensus estimate of -$1.42 by $0.41. Quarterly revenue was reported to be $0.60 million, below the consensus estimate of $6.65 million. With a trailing EPS of -$2.83, CRISPR Therapeutics' earnings are expected to decrease next year, from ($5.13) to ($5.22) per share. Get CRISPR Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CRISPR Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCRSP Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CRSP Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. CRISPR Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20244-$1.98-$1.19-$1.59Q2 20244-$1.98-$1.14-$1.63Q3 20244-$1.83-$1.18-$1.55Q4 20244-$1.52-$0.74-$1.22FY 202416-$7.31-$4.25-$5.99Q1 20252-$1.51-$1.03-$1.27Q2 20252-$1.48-$0.97-$1.23Q3 20252-$1.39-$0.92-$1.16Q4 20252-$1.32-$0.38-$0.85FY 20258-$5.70-$3.30-$4.50Q1 20261-$1.40-$1.40-$1.40Q2 20261-$1.11-$1.11-$1.11Q3 20261-$0.60-$0.60-$0.60 CRISPR Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails11/5/2024Q3 2024-$1.42-$1.01+$0.41-$1.01$6.65M$0.60M8/5/2024Q2 2024-$1.43-$1.49 -$0.06-$1.49$12.31M$0.52M5/8/2024Q1 2024-$1.35-$1.43 -$0.08-$1.43$25.53M$0.50M2/21/2024Q4 2023$0.15$1.10+$0.95$1.10$148.72M$201.20M11/6/2023Q3 2023-$2.04-$1.41+$0.63-$1.41$5.05M-8/7/2023Q2 2023-$2.13-$0.98+$1.15-$0.98$1.80M$70.00M Get the Latest News and Ratings for CRSP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/8/2023Q1 2023-$1.64-$0.67+$0.97-$0.67$24.33M$100.00M2/21/2023Q4 2022-$2.27-$1.41+$0.86-$1.41$7.37M$6.00M CRISPR Therapeutics Earnings - Frequently Asked Questions When did CRISPR Therapeutics announce their last quarterly earnings? CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earning data on Tuesday, November 5, 2024. Learn more on CRSP's earnings history. Did CRISPR Therapeutics beat their earnings estimates last quarter? In the previous quarter, CRISPR Therapeutics (NASDAQ:CRSP) reported ($1.01) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.42) by $0.41. Learn more on analysts' earnings estimate vs. CRSP's actual earnings. How much revenue does CRISPR Therapeutics generate each year? CRISPR Therapeutics (NASDAQ:CRSP) has a recorded annual revenue of $200 million. How much profit does CRISPR Therapeutics generate each year? CRISPR Therapeutics (NASDAQ:CRSP) has a recorded net income of -$153.61 million. CRSP has generated -$2.83 earnings per share over the last four quarters. What is CRISPR Therapeutics's EPS forecast for next year? CRISPR Therapeutics's earnings are expected to decrease from ($5.13) per share to ($5.22) per share in the next year. More Earnings Resources from MarketBeat Related Companies Neurocrine Biosciences Earnings Date Bio-Techne Earnings Date Vaxcyte Earnings Date Qiagen Earnings Date Exelixis Earnings Date Repligen Earnings Date Revolution Medicines Earnings Date Halozyme Therapeutics Earnings Date Krystal Biotech Earnings Date ADMA Biologics Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings Report URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now This page (NASDAQ:CRSP) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partnersliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredThe Key to Feeding 8.1 Billion PeopleImagine a mineral so small it fits in the palm of your hand... yet its potential could transform the world's f...i2i Marketing Group, LLC | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
